Last $17.08 USD
Change Today -0.09 / -0.52%
Volume 624.3K
THRX On Other Exchanges
As of 8:10 PM 10/24/14 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Rick E. Winningham

Chairman of the Board, Member of Stock Option Committee and Member of Science & Technology Advisory Committee, Theravance Inc.
AgeTotal Calculated CompensationThis person is connected to 68 board members in 5 different organizations across 5 different industries.

See Board Relationships
As of Fiscal Year 2013


Mr. Rick E Winningham was the Chief Executive Officer of Theravance Inc. since October 2001 until August 15, 2014. Mr. Winningham served as President of Theravance Inc. since October 2001. From 1997 to 2001, Mr. Winningham served as the President, Bristol-Myers Squibb Oncology /Immunology /Oncology Therapeutics Network (OTN) and as the President of Global Marketing from 2000 to 2001. In addition to operating responsibility for U.S. Oncology/Immunology/OTN at Bristol-Myers ...

Read Full Background

Corporate Headquarters*

901 Gateway Boulevard
South San Francisco, California 94080

United States

Phone: 650-238-9600
Fax: --

Board Members Memberships*

Chairman of the Board, Member of Stock Option Committee and Member of Science & Technology Advisory Committee
Lead Independent Director, Member of Compensation Committee and Member of Nominating & Corporate Governance Committee


Texas Christian University
Southern Illinois University, Carbondale Campus

Other Affiliations*

Annual Compensation*

Total Annual Compensation$986,944

Stock Options*

Restricted Stock Awards$244,420
All Other Compensation$500
Exercised Options385,161
Exercised Options Value$9,267,937
Exercisable Options138,710
Exercisable Options Value$530,566
Total Value of Options$9,798,502
Total Number of Options523,871

Total Compensation*

Total Annual Cash Compensation$1,503,460
Total Short Term Compensation$986,944
Other Long Term Compensation$244,920
Total Calculated Compensation$1,747,880
*Data is at least as current as the most recent Definitive Proxy.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
THRX:US $17.08 USD -0.09


Howard W. Robin Chief Executive Officer, President and Director
Nektar Therapeutics
Peter M. Hecht Ph.D. Co-Founder, Chief Executive Officer and Director
Ironwood Pharmaceuticals, Inc.
Mark R. Baker J.D.Chief Executive Officer, Director and Member of Science & Strategy Committee
Progenics Pharmaceuticals, Inc.
Peter S. Greenleaf Chief Executive Officer, Director, Member of Commercialization Committee and Member of Science & Technology Committee
Sucampo Pharmaceuticals, Inc.
Richard Martin Steeves Ph.D.Group Chief Executive Officer, Member of Senior Executive Board and Executive Director
Synergy Health plc
823.0K GBP
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact THERAVANCE INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at